human growth hormone comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-02-12. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
A 2017 film adaptation of Wonder, starring Julia Roberts, Owen Wilson and Jacob Tremblay, was released in November 2017. A stage adaption premiered in 2025, with actor Garrett McNally, who has Treacher Collins syndrome himself, portraying the character in certain shows. Alison Midstokke, who appears in the drama film Happy Face (2018), is an actress and activist who has the condition.
The jararaca (Bothrops jararaca) is a species that is often abundant within its range, where it is an important cause of snakebite. It is the best-known venomous snake in the wealthy and heavily populated areas of southeastern Brazil, where it was responsible for 52% (3,446 cases) of snakebites between 1902 and 1945, with a 0.7% mortality rate (25 deaths). The average venom yield is 25–26 milligrams (0.39–0.40 gr) with a maximum of 300 milligrams (4.6 gr) of dried venom. The venom is slightly more toxic than that of the terciopelo or fer-de-lance (B. asper). In mice, the median lethal dose (LD50) is 1.2–1.3 mg/kg IV, 1.4 mg/kg IP and 3.0 mg/kg SC. The lethal dose for a 60 kg adult human is 70 mg.
Federal funding was included in the Biden administration's Bipartisan Infrastructure Bill, which became law in November 2021, and Biden announced in 2023 that the federal government was committing as much as $11 billion of the $16.1 billion price tag, with the states of New York and New Jersey splitting the rest. Construction of the new Hudson River tunnel began in late 2023 and was underway as of 2026, despite being briefly interrupted by the freezing of funds by the Trump administration for various reasons overturned by judges. The new tunnel is scheduled to open in 2035, with refurbishment of the old tunnels and increased capacity by 2038.
Danyelle M. Townsend is a biomedical scientist, and academic. She is a Professor and acting Department Chair of Drug Discovery and Biomedical Sciences at the Medical University of South Carolina (MUSC). Townsend's lab utilizes proteomics and analytical biochemistry to identify molecular targets affected by oxidative and nitrosative stress, exploring the impact of redox signaling on cellular responses. Her research on the redox proteome and associated pathways has contributed to drug discovery and redox biomarker development. Townsend has authored over 150 peer-reviewed publications including journal articles, book chapters, and co-edited a book titled, Redox and Cancer Part A. In addition, she served as Co-Editor for Biomedicine and Pharmacotherapy from 2014 to 2015, and has been the Editor-in-Chief for this journal since 2015.
=== Counterfeits === In October 2023, there were reports of counterfeit Ozempic pens being sold in Europe. The pens possibly contained insulin, and led to several people being hospitalised with hypoglycemia and seizures. In December 2023, the US FDA issued a warning about counterfeit Ozempic.
Sources: en.wikipedia.org
==== Kinetics of antibody response ==== Humoral responses after a single DNA injection can be much longer-lived than after a single injection with a recombinant protein. Antibody responses against hepatitis B virus (HBV) envelope protein (HBsAg) have been sustained for up to 74 weeks without boost, while lifelong maintenance of protective response to influenza haemagglutinin was demonstrated in mice after gene gun delivery. Antibody-secreting cells (ASC) migrate to the bone marrow and spleen for long-term antibody production, and generally localise there after one year. Comparisons of antibody responses generated by natural (viral) infection, immunization with recombinant protein and immunization with pDNA are summarised in Table 4. DNA-raised antibody responses rise much more slowly than when natural infection or recombinant protein immunization occurs. As many as 12 weeks may be required to reach peak titres in mice, although boosting can decrease the interval. This response is probably due to the low levels of antigen expressed over several weeks, which supports both primary and secondary phases of antibody response. DNA vaccine expressing HBV small and middle envelope protein was injected into adults with chronic hepatitis. The vaccine resulted in specific interferon gamma cell production. Also specific T-cells for middle envelop proteins antigens were developed. The immune response of the patients was not robust enough to control HBV infection
== Selected publications == Araujo JV, Davidenko N, Danner M, Cameron RE, Best SM: Novel Porous scaffolds of pH Responsive Chitosan/Carrageenan-based Polyelectrolyte Complexes for Tissue Engineering. J Biomed Mater Res A. 2014 Feb 14. Pawelec KM, Husmann A, Best SM, Cameron RE: Understanding anisotropy and architecture in ice-templated biopolymer scaffolds. Mater Sci Eng C Mater Biol Appl. 2014 Apr 1;37:141-7. Pawelec KM, Husmann A, Best SM, Cameron RE: A design protocol for tailoring ice-templated scaffold structure. J R Soc Interface. 2014 Jan 8;11(92):20130958. Shepherd JH, Ghose S, Kew SJ, Moavenian A, Best SM, Cameron RE: Effect of fiber crosslinking on collagen-fiber reinforced collagen-chondroitin-6-sulfate materials for regenerating load-bearing soft tissues. J Biomed Mater Res A. 2013 Jan;101(1):176-84. Kew SJ, Gwynne JH, Enea D, Brookes R, Rushton N, Best SM, Cameron RE: Synthetic collagen fascicles for the regeneration of tendon tissue. Acta Biomater. 2012 Oct;8(10):3723-31. Grover CN, Gwynne JH, Pugh N, Hamaia S, Farndale RW, Best SM, Cameron RE: Crosslinking and composition influence the surface properties, mechanical stiffness and cell reactivity of collagen-based films. Acta Biomater. 2012 Aug;8(8):3080-90. Grover CN, Farndale RW, Best SM, Cameron RE: The interplay between physical and chemical properties of protein films affects their bioactivity. J Biomed Mater Res A. 2012 Sep;100(9):2401-11.
=== Other === Arterial stiffness Arthrofibrosis (knee, shoulder, other joints) Chronic kidney disease Crohn's disease (intestine) Dupuytren's contracture (hands, fingers) Keloid (skin) Lipedema (fat cells, typically in lower limbs) Mediastinal fibrosis (soft tissue of the mediastinum) Myelofibrosis (bone marrow) Myofibrosis (skeletal muscle) Peyronie's disease (penis) Nephrogenic systemic fibrosis (skin) Progressive massive fibrosis (lungs); a complication of pneumoconiosis Retroperitoneal fibrosis (soft tissue of the retroperitoneum) Scleroderma/systemic sclerosis (skin, lungs) Some forms of adhesive capsulitis (shoulder) Fibrosis reversal Historically, fibrosis was considered an irreversible process. However, several recent studies have demonstrated reversal in liver and lung tissue, and in cases of renal, myocardial, and oral-submucosal fibrosis.
In the skin, systemic sclerosis causes hardening and scarring. The skin may appear tight, reddish, or scaly. Blood vessels may also be more visible. Where large areas are affected, fat and muscle wastage may weaken limbs and affect appearance. Patients report severe and recurrent itching of large skin areas. The severity of these symptoms varies greatly among patients: Some having scleroderma of only a limited area of the skin (such as the fingers) and little involvement of the underlying tissue, while others have progressive skin involvement. Digital ulcers—open wounds especially on fingertips and less commonly the knuckles—are not uncommon.
Although rubidium is more abundant in Earth's crust than caesium, the limited applications and the lack of a mineral rich in rubidium limits the production of rubidium compounds to 2 to 4 tonnes per year. Several methods are available for separating potassium, rubidium, and caesium. The fractional crystallization of a rubidium and caesium alum (Cs,Rb)Al(SO4)2·12H2O yields after 30 subsequent steps pure rubidium alum. Two other methods are reported, the chlorostannate process and the ferrocyanide process. For several years in the 1950s and 1960s, a by-product of potassium production called Alkarb was a main source for rubidium. Alkarb contained 21% rubidium, with the rest being potassium and a small amount of caesium. Today the largest producers of caesium produce rubidium as a by-product from pollucite.
Sources: en.wikipedia.org
Iranian officials described the attack as an attempt to derail diplomacy, noting that Kharazi was overseeing a possible meeting between Iranian officials and US vice president JD Vance. Airstrikes on the strategically important Hengam Island in the Strait of Hormuz caused seven injuries. Netanyahu asserted that the US–Israeli strikes have eliminated Iran's ability to produce nuclear weapons and ballistic missiles, thereby removing "two existential threats" to Israel. Late in the day on 1 April, Trump made a speech addressing the nation, in which he said that the strikes have "dramatically curtailed" Iranian missile and drone systems, and added that the attacks on Iran will escalate over the next two to three weeks to "bring them back to the Stone Ages, where they belong". On 2 April, two US strikes on the B1 bridge between Tehran and Karaj, which was described as the highest bridge in the Middle East, reportedly killed eight people and wounded 95 others, causing it to collapse. Experts assessed the attack as a possible war crime; it was celebrated by Trump. At the time of the attack, many Iranian families had been gathered in the parks below the bridge to celebrate Sizdah Be-dar. Iran revealed major damage to the century-old medical center Pasteur Institute of Iran. US defense secretary Hegseth boasted of "death and destruction from the sky all day long". The IDF also announced that one of its strikes in the Kermanshah area of Iran killed Iranian ballistics missile chief Makram Atimi and several battalion commanders from Atimi's central Iranian ballistic missile unit.
== History == On August 10, 1863, the Napa Valley Register first published. It was founded by J.I. Horrell as a pro-Union paper, in contrast to the pro-Succession Napa Echo. By 1864, the newspaper had dropped “Valley” from its name, becoming simply the Napa Register, until returning to the original name over a century later. Editor R.T. Montgomery retired from the paper in January 1866. He returned that May and sold it to N.E. White in January 1868. White left after six months and Montgomery returned again, only to later sell the Register a second time in November 1869 to R.D. Hopkins, formerly editor of the Vallejo Recorder. Hopkins sold to Rev. George W. Henning and George M. Francis in February 1872. The Register moved to daily publication in December 1872. Henning sold out to Charles A. Gardner in May 1873. Gardner left after a few years to run the St. Helena Star. George M. Francis became sole owner of the Register in 1878, upon the death of his business partner. Francis was succeeded in ownership by his son George H. Francis in 1932. The paper remained with Francis and various partners until 1958, when it was sold to Scripps League Newspapers. Scripps was acquired by Pulitzer in 1996, and Pulitzer was acquired by Lee Enterprises in 2005. Dan Evans became the paper's editor in March 2022, and he soon unveiled a newly reconstituted editorial board that October. The board was made up of three members of the newspaper's staff and seven community members. It aimed to assist in driving the official opinion of the paper. In April 2023, the paper laid off two employees.
== Ecological lifetime == A poison which enters the food chain—whether of industrial, agricultural, or natural origin—might not be immediately toxic to the first organism that ingests the toxin, but can become further concentrated in predatory organisms further up the food chain, particularly carnivores and omnivores, especially concerning fat soluble poisons which tend to become stored in biological tissue rather than excreted in urine or other water-based effluents. Apart from food, many poisons readily enter the body through the skin and lungs. Hydrofluoric acid is a notorious contact poison, in addition to its corrosive damage. Naturally occurring sour gas is a fast-acting atmospheric poison, which can be released by volcanic activity or drilling rigs. Plant-based contact irritants, such as that possessed by poison ivy, are often classed as allergens rather than poisons; the effect of an allergen being not a poison as such, but to turn the body's natural defenses against itself. Poison can also enter the body through faulty medical implants, or by injection (which is the basis of lethal injection in the context of capital punishment). In 2013, 3.3 million cases of unintentional human poisonings occurred. This resulted in 98,000 deaths worldwide, down from 120,000 deaths in 1990. In modern society, cases of suspicious death elicit the attention of the Coroner's office and forensic investigators.
The Moscow Metro operates a short monorail line (line 13). This line connects the Timiryazevskaya metro station and Ulitsa Sergeya Eisensteina (street), passing near the Exhibition of Achievements of National Economy (VDNKh) (and the Line 6 Metro station VDNKh). The monorail line opened in 2004. It permits above-ground transfers; a passenger does not need to pay any additional fare if they took another ride on the Moscow Metro within the most recent 90 minutes.
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.